A2/A2B to B Kidney Transplantation Outcomes: A Single-Center 5 Year Experience
Clazakizumab® (anti-il-6) Desensitization in Highly-HLA Sensitized Patients Awaiting Kidney Transplant (nct03380962): Long-Term Follow Up
Desensitization Protocol Consisting of High-Dose Intravenous Immunoglobulin, Plasmapheresis, and Rituximab in Highly Sensitized Kidney Transplant Recipients
Desensitization Protocol to Prevent Severe Oliguric Antibody-Mediated Rejection
Early Clinical Complications Following HLA-Incompatible Living Donor Kidney Transplantation
Excellent Long-Term Outcome of ABO-Incompatible Living Kidney Transplantation by Reduced-Session of Plasmapheresis of Desensitization Protocol
Ixazomib for Desensitization (IXADES): Results of a Phase II Clinical Trial
Obinutuzumab in Kidney Transplantation: Effect on B-cell Counts and Crossmatch Tests
Outcomes of Hlai Kidney Transplants in Patients with Cpra 100% After Desensitization
Outcomes of Post-Operative Plasmapheresis in African American Kidney Transplant Recipients with High Panel Reactive Antibodies – A Single Center Experience
2022 American Transplant Congress